Anika Therapeutics (ANIK) Change in Accured Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Change in Accured Expenses data on file, last reported at -$1.3 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.3 million, up 56.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $249000.0 (up 106.83% YoY), and the FY2025 annual result was -$1.5 million, up 59.12% from the prior year.
• Change in Accured Expenses eased to -$1.3 million in Q1 2026 per ANIK's latest filing, from $141000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.6 million in Q3 2023 and troughed at -$4.3 million in Q2 2023.
• A 5-year average of -$311941.2 and a median of -$558000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses soared 255.3% in 2023, then tumbled 567.67% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$558000.0 in 2022, then soared by 231.54% to $734000.0 in 2023, then slumped by 227.38% to -$935000.0 in 2024, then jumped by 115.08% to $141000.0 in 2025, then plunged by 1049.65% to -$1.3 million in 2026.
• Business Quant data shows ANIK's Change in Accured Expenses at -$1.3 million in Q1 2026, $141000.0 in Q4 2025, and $3.6 million in Q3 2025.